Inicio>>Gemcitabine monophosphate disodium salt

Gemcitabine monophosphate disodium salt (Synonyms: Gemcitabine monophosphate disodium salt monohydrate; Gemcitabine monophosphate disodium; GemMP.)

Catalog No.GB62201

Gemcitabine monophosphate disodium salt, also called GemMP, is a monophosphate derivative of Gemcitabine.

Products are for research use only. Not for human use. We do not sell to patients.

Gemcitabine monophosphate disodium salt Chemical Structure

Cas No.: 1638288-31-9

Tamaño Precio Disponibilidad Cantidad
5mg
150,00 $
Disponible
10mg
250,00 $
Disponible
25mg
450,00 $
Disponible
50mg
750,00 $
Disponible
100mg
1.350,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents
Gemcitabine monophosphate disodium salt, also called GemMP, is a monophosphate derivative of Gemcitabine. Gemcitabine (Gem) is a deoxycytidine analog that is effective against pancreatic cancer and other malignancies following conversion to the 5'-O-mono-, di- and tri-phosphate forms. GemMP decreased tumor cell growth at concentrations ranging from 1 to 50 nM. GemMP is a potent cytotoxic agent that serves to induce apoptosis in association with increased Fas expression in cultured thyroid cancer cell lines. (Anticancer Res. 2000 Sep-Oct;20(5A):2915-22). Note: Current batch has purity ~ 90%.

Reseñas

Review for Gemcitabine monophosphate disodium salt

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Gemcitabine monophosphate disodium salt

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.